Prevalence of COVID-19-like Symptoms among People Living with HIV, and Using Antiretroviral Therapy for Prevention and Treatment

Author(s): SeyedAhmad SeyedAlinaghi, Maryam Ghadimi, Mahboubeh Hajiabdolbaghi, Mehrnaz Rasoolinejad, Ladan Abbasian, Malihe Hassan Nezhad, SeyedAli Dehghan Manshadi, Fatemeh Ghadimi, Zahra Ahmadinejad*

Journal Name: Current HIV Research
HIV and Viral Immune Diseases

Volume 18 , Issue 5 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: COVID-19 has spread globally with remarkable speed, and currently, there is limited data available exploring any aspect of the intersection between HIV and SARSCoV- 2 co-infection.

Objective: To estimate the prevalence of clinical symptoms associated with COVID-19 among people living with HIV (PLWH) in Tehran, Iran.

Design: Cross-sectional study.

Methods: A total of 200 PLWH were recruited through the positive club via sampling, and completed the symptom-based questionnaire for COVID-19, which was delivered by trained peers.

Results: Of 200 participants, respiratory symptoms, including cough, sputum, and shortness of breath, were the most prevalent among participants, but only one person developed symptoms collectively suggested COVID-19 and sought treatments.

Conclusion: It appears that existing infection with HIV or receiving antiretroviral treatment (ART) might reduce the susceptibility to the infection with SARS-CoV-2 or decrease the severity of the infection acquired. Further research is needed to understand causal mechanisms.

Keywords: COVID-19, coronavirus, SARS-CoV-2, pneumonia, HIV, antiretroviral treatment (ART).

[1]
WHO Who director-general's opening remarks at the media briefing on covid-19 - 11 march 2020: World Health Organization 2020 Available at: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
[2]
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (covid-19) outbreak in china: Summary of a report of 72é  314 cases from the chinese center for disease control and prevention. JAMA 2020. [Online ahead of print].
[http://dx.doi.org/10.1001/jama.2020.2648] [PMID: 32091533]
[3]
Asadollahi-Amin A, Hasibi M, Ghadimi F, et al. Lung Involvement Found on Chest CT Scan in a Pre-Symptomatic Person with SARS-CoV-2 Infection: A Case Report. Trop Med Infect Dis 2020; 5(2): E56
[4]
Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan. China: JAMA 2020. [Online ahead of print].
[http://dx.doi.org/10.1001/jama.2020.1585]
[5]
Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368: m1091.
[http://dx.doi.org/10.1136/bmj.m1091] [PMID: 32217556]
[6]
Arentz M, Yim E, Klaff L, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA 2020. [Online ahead of print].
[http://dx.doi.org/10.1001/jama.2020.4326] [PMID: 32191259]
[7]
Cao J, Tu WJ, Cheng W, et al. Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, China. Clin Infect Dis 2020 [Online ahead of print]
[8]
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395(10229): 1033-4.
[http://dx.doi.org/10.1016/S0140-6736(20)30628-0] [PMID: 32192578]
[9]
Wang C, Kang K, Gao Y, et al. Cytokine Levels in the Body Fluids of a Patient With COVID-19 and Acute Respiratory Distress Syndrome: A Case Report. Ann Intern Med 2020. [Online ahead of print].
[http://dx.doi.org/10.7326/L20-0354] [PMID: 32422085]
[10]
Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré Syndrome Associated with SARS-CoV-2. N Engl J Med 2020; 382(26): 2574-6.
[http://dx.doi.org/10.1056/NEJMc2009191] [PMID: 32302082]
[11]
Ghiasvand F, Ghadimi M, Ghadimi F, Safarpour S, Hosseinzadeh R. SeyedAlinaghi S. Symmetrical polyneuropathy in coronavirus disease 2019 (COVID-19). IDCases 2020; 21: e00815
[http://dx.doi.org/10.1016/j.idcr.2020.e00815] [PMID: 32514394]
[12]
WHO. WHO emergency covid-19 dashboard 2020. Available at: https://covid19.who.int/region/emro/country/ir
[13]
WHO. People who are at higher risk for severe illness: World Health Organizaiton 2020. Available at: . https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html
[14]
WHO Q&A on covid-19, hiv and antiretrovirals: World Health Organization 2020 Available at: https://www.who.int/news-room/q-a-detail/q-a-on-covid-19-hiv-and-antiretrovirals
[15]
Brown J, Roy A, Harris R, et al. Respiratory symptoms in people living with HIV and the effect of antiretroviral therapy: a systematic review and meta-analysis. Thorax 2017; 72(4): 355-66.
[http://dx.doi.org/10.1136/thoraxjnl-2016-208657] [PMID: 27965402]
[16]
Head BM, Mao R, Keynan Y, Rueda ZV. Inflammatory mediators and lung abnormalities in HIV: A systematic review. PLoS One 2019; 14(12): e0226347
[http://dx.doi.org/10.1371/journal.pone.0226347] [PMID: 31830103]
[17]
SeyedAlinaghi S. Hiv in iran: Epidemiology, response, challenges and way forward. AIDS 2019 [ In Press].
[18]
Najafi Z, Taj L, Dadras O, Ghadimi F, Moradmand S. SeyedAlinaghi S. Epidemiology of Hiv in iran. Curr HIV Res 2020. [Online ahead of print].
[http://dx.doi.org/10.2174/1570162X18666200605152317]
[19]
Razai MS, Doerholt K, Ladhani S, Oakeshott P. Coronavirus disease 2019 (covid-19): a guide for UK GPs. BMJ 2020; 368: m800.
[http://dx.doi.org/10.1136/bmj.m800] [PMID: 32144127]
[20]
Azadmanesh K. National interim guidelines for the management of covid-19 2020.Available at: http://corona.behdasht.gov.ir/files/site1/files/Covid-19_Treatment_Flowcharts.pd
[21]
Autenrieth CS, Beck EJ, Stelzle D, Mallouris C, Mahy M, Ghys P. Global and regional trends of people living with HIV aged 50 and over: Estimates and projections for 2000-2020. PLoS One 2018; 13(11): e0207005
[http://dx.doi.org/10.1371/journal.pone.0207005] [PMID: 30496302]
[22]
WHO Chronic comorbidities and coinfections in people living with hiv : World Health Organization 2020 Available at: https://www.who.int/hiv/topics/comorbidities/about/en/
[23]
Ghosn J, Taiwo B, Seedat S, Autran B, Katlama C. Hiv Lancet 2018; 392(10148): 685-97.
[http://dx.doi.org/10.1016/S0140-6736(18)31311-4] [PMID: 30049419]
[24]
Lim J, Jeon S, Shin HY, et al. Case of the index patient who caused tertiary transmission of covid-19 infection in korea: The application of lopinavir/ritonavir for the treatment of covid-19 infected pneumonia monitored by quantitative rt-pcr. J Korean Med Sci 2020; 35(6): e79-9.
[http://dx.doi.org/10.3346/jkms.2020.35.e79] [PMID: 32056407]
[25]
Liu F, Xu A, Zhang Y, et al. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis 2020; 95: 183-91.
[http://dx.doi.org/10.1016/j.ijid.2020.03.013] [PMID: 32173576]
[26]
Ye XT, Luo YL, Xia SC, et al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci 2020; 24(6): 3390-6.
[PMID: 32271456]
[27]
Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. New Engl J Med 2020; 20: 282.
[http://dx.doi.org/10.1056/NEJMoa2001282]
[28]
Li Y, Xie Z, Lin W, et al. An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate covid-19 (elacoi). medRxiv 2020; 5: 24.
[29]
Zhu F, Cao Y, Xu S, Zhou M. Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China. J Med Virol 2020; 92(6): 529-30.
[http://dx.doi.org/10.1002/jmv.25732] [PMID: 32160316]
[30]
Zhao J, Liao X, Wang H, et al. Early virus clearance and delayed antibody response in a case of coronavirus disease 2019. (covid-19) with a history of coinfection with human immunodeficiency virus type 1 and hepatitis c virus. Clin Infect Dis 2020. ciaa408..
[http://dx.doi.org/10.1093/cid/ciaa408]
[31]
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8(4): 420-2.
[http://dx.doi.org/10.1016/S2213-2600(20)30076-X] [PMID: 32085846]
[32]
Romanelli A, Mascolo S. Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019: A therapeutical hypothesis. Am J Transplant 2020. [Online ahead of print].
[http://dx.doi.org/10.1111/ajt.15905] [PMID: 32243698]
[33]
Ghiasvand F, Miandoab SZ, Harandi H, Golestan FS, Alinaghi SAS. A Patient with COVID-19 Disease in a Referral Hospital in Iran: A Typical Case. [published online ahead of print, 2020 Apr 29]. Infect Disord Drug Targets 2020.
[http://dx.doi.org/10.2174/1871526520666200429115535]
[34]
Mehraeen E, Behnezhad F, Salehi MA, Noori T, Harandi H. SeyedAlinaghi S. Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of current evidence. [published online ahead of print, 2020 Jun 17]. Eur Arch Otorhinolaryngol 2020; 1-6.
[http://dx.doi.org/10.1007/s00405-020-06120-6]
[35]
Sadr S. SeyedAlinaghi S, Ghiasvand F, et al. Isolated severe thrombocytopenia in a patient with COVID-19: A case report. IDCases. 2020;21:e00820. Published 2020 May 29
[http://dx.doi.org/10.1016/j.idcr.2020.e00820]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 5
Year: 2020
Published on: 12 July, 2020
Page: [373 - 380]
Pages: 8
DOI: 10.2174/1570162X18666200712175535
Price: $65

Article Metrics

PDF: 62
HTML: 2
PRC: 1